Researchers found that F-18 FDG-PET parameter changes during therapy predicted time to progression and time to skeletal-related event, but not overall survival, among patients with bone-dominant metastatic breast cancer, while serial F-18 NaF-PET was related to OS, but not TTP and tSRE. The findings in the Journal of Nuclear Medicine suggest that F-18 FDG could serve as a response endpoint that may enable better access to clinical trials and new treatments among these patients, researchers wrote.
Study compares PET tracers in bone-dominant metastatic breast cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.